OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions for life sciences companies, has confirmed receiving a notice of nominations from stockholder Whetstone Capital Advisors, . The notice indicates Whetstone's intention to nominate two candidates for election to the OptimizeRx Board of Directors at the company's 2025 Annual Meeting of Stockholders.
The OptimizeRx Board will review the nominations and provide their formal recommendation in the upcoming definitive proxy statement, which will be filed with the SEC and distributed to eligible voting stockholders. The company emphasized that no stockholder action is currently required, and the 2025 Annual Meeting date has not yet been scheduled.
OptimizeRx (Nasdaq: OPRX), un fornitore leader di soluzioni tecnologiche sanitarie per aziende delle scienze della vita, ha confermato di aver ricevuto un avviso di nomine da parte dell'azionista Whetstone Capital Advisors. L'avviso indica l'intenzione di Whetstone di nominare due candidati per l'elezione nel Consiglio di Amministrazione di OptimizeRx durante il 2025 Annual Meeting of Stockholders dell'azienda.
Il Consiglio di Amministrazione di OptimizeRx esaminerà le nomine e fornirà il proprio parere formale nella prossima dichiarazione di delega definitiva, che sarà presentata alla SEC e distribuita agli azionisti aventi diritto al voto. L'azienda ha sottolineato che attualmente non è richiesta alcuna azione da parte degli azionisti e che la data del Meeting Annuale del 2025 non è stata ancora programmata.
OptimizeRx (Nasdaq: OPRX), un proveedor líder de soluciones tecnológicas de salud para empresas de ciencias de la vida, ha confirmado haber recibido un aviso de nominaciones por parte del accionista Whetstone Capital Advisors. El aviso indica la intención de Whetstone de nominar a dos candidatos para la elección en la Junta Directiva de OptimizeRx durante la Reunión Anual de Accionistas de 2025 de la empresa.
La Junta Directiva de OptimizeRx revisará las nominaciones y proporcionará su recomendación formal en la próxima declaración de poder definitiva, que será presentada a la SEC y distribuida a los accionistas elegibles para votar. La empresa enfatizó que actualmente no se requiere ninguna acción por parte de los accionistas y que la fecha de la Reunión Anual de 2025 aún no ha sido programada.
OptimizeRx (Nasdaq: OPRX), 생명과학 기업을 위한 의료 기술 솔루션의 선도적인 제공업체는 주주 Whetstone Capital Advisors로부터 후보 지명 통지를 받았음을 확인했습니다. 이 통지는 Whetstone이 OptimizeRx 이사회에 두 명의 후보를 지명할 의도를 나타냅니다, 회사의 2025년 주주 연례 회의에서.
OptimizeRx 이사회는 지명을 검토하고 SEC에 제출될 예정인 차기 확정 위임장에 대한 공식 권고를 제공할 것입니다, 이는 투표할 자격이 있는 주주에게 배포됩니다. 회사는 현재 주주 행동이 필요하지 않으며, 2025년 연례 회의 날짜는 아직 정해지지 않았다고 강조했습니다.
OptimizeRx (Nasdaq: OPRX), un fournisseur leader de solutions technologiques de santé pour les entreprises des sciences de la vie, a confirmé avoir reçu un avis de nominations de l'actionnaire Whetstone Capital Advisors. L'avis indique l'intention de Whetstone de nommer deux candidats pour l'élection au Conseil d'Administration d'OptimizeRx lors de la Réunion Annuelle des Actionnaires de 2025 de l'entreprise.
Le Conseil d'Administration d'OptimizeRx examinera les nominations et fournira sa recommandation formelle dans la prochaine déclaration de procuration définitive, qui sera déposée auprès de la SEC et distribuée aux actionnaires éligibles au vote. L'entreprise a souligné qu'aucune action des actionnaires n'est actuellement requise et que la date de la Réunion Annuelle de 2025 n'a pas encore été fixée.
OptimizeRx (Nasdaq: OPRX), ein führender Anbieter von Gesundheitstechnologielösungen für Unternehmen der Lebenswissenschaften, hat bestätigt, eine Nominierungsbenachrichtigung von dem Aktionär Whetstone Capital Advisors erhalten zu haben. Die Benachrichtigung weist auf Whetstones Absicht hin, zwei Kandidaten für die Wahl in den Vorstand von OptimizeRx während der Jahreshauptversammlung der Aktionäre 2025 zu nominieren.
Der Vorstand von OptimizeRx wird die Nominierungen prüfen und seine formelle Empfehlung in der bevorstehenden endgültigen Vollmachtserklärung abgeben, die bei der SEC eingereicht und an wahlberechtigte Aktionäre verteilt wird. Das Unternehmen betonte, dass derzeit keine Aktion von den Aktionären erforderlich ist und dass das Datum der Jahreshauptversammlung 2025 noch nicht festgelegt wurde.
- None.
- None.
No Stockholder Action Required at this Time
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company’s 2025 Annual Meeting of Stockholders.
The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company’s definitive proxy statement which will be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company’s 2025 Annual Meeting of Stockholders, which has not yet been scheduled.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
Important Additional Information And Where To Find It
OptimIzeRx Corporation (the “Company”) plans to file proxy materials with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for the Company's 2025 annual meeting of stockholders (the “2025 Annual Meeting”). Prior to the 2025 Annual Meeting, the Company will file a definitive proxy statement (the “Proxy Statement”) together with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) when filed by the Company with the SEC at the SEC's website (http://www.sec.gov) or at the Company's website at https://www.optimizerx.com/ or by contacting Andy D’Silva, SVP - Finance, by email at adsilva@optimizerx.com or by mail at OptimizeRx Corporation, 260 Charles Street, Suite 302, Waltham, MA 02453.
Certain Information Regarding Participants
The Company, its directors, certain of its executive officers, and other employees may be deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting. Additional information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting. Information relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement, such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form 4 filed with the SEC with respect to the Company: Form 4, filed by Stephen L. Silvestro on March 4, 2025; Form 4, filed by Stephen L. Silvestro on February 20, 2025; Form 4, filed by Edward Stelmakh on February 20, 2025; Form 4, filed by Cathy Klema on February 4, 2025; Form 4/A, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Stephen L. Silvestro on December 27, 2024; Form 4, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Edward Stelmakh on December 20, 2024; Form 4, filed by Stephen L. Silvestro on December 20, 2024; Form 4, filed by Edward Stelmakh on October 15, 2024; Form 4, filed by Stephen L. Silvestro on October 7, 2024; Form 4, filed by Edward Stelmakh on October 7, 2024; Form 4, filed by Gregory D. Wasson on June 11, 2024; Form 4, filed by Cathy Klema on June 11, 2024; Form 4, filed by Ellen O’Connor Vos on June 11, 2024; Form 4, filed by James Paul Lang on June 11, 2024; Form 4, filed by Patrick Spangler on June 11, 2024; Form 4/A, filed by Stephen L. Silvestro on May 6, 2024; Form 4, filed by Stephen L. Silvestro on May 6, 2024; and Form 4/A, filed by Stephen L. Silvestro on May 6, 2024. These filings can be found at the SEC's website at www.sec.gov. More detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Sandya von der Weid
LifeSci Advisors, LLC
svonderweid@lifesciadvisors.com
FAQ
What is the purpose of Whetstone Capital's director nominations for OPRX?
When will OPRX shareholders vote on the proposed director nominations?
What actions are required from OPRX stockholders regarding the nominations?
How will OPRX's Board respond to Whetstone Capital's director nominations?
